Saturday 17 October 2026
Export ABPO’s income statement to Excel — free account
Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023. In the quarter to June 2026, EPS grew 89.3% and free cash flow was flat, each against the same quarter a year earlier.
0.36
0.05
−12.20%
Follow ABPO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 296.10 | 293.70 | 28.50 | 3.78 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 307.20 | 333.45 | 390.00 | 54.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 6 | 3 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.03 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | — | |||||
| EBT | — | — | — | — | — | 0 | 2 | (12) | (7) | (3) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | (9,595.08) | (3,951.91) | 0.00 | |||||
| Net income | — | 0 | — | — | — | 0 | 1 | (12) | (7) | (3) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.19 | 0.23 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | 3.55 | (18.37) | (22.22) | (1.30) | |||||
| Cash flow | — | — | — | — | — | 0.00 | (4.74) | (11.62) | (11.58) | (2.69) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.08) | 0.00 | 0.01 | |||||
| Free cash flow | — | — | — | — | — | 0.00 | (4.74) | (11.69) | (11.58) | (2.68) | |||||
| Book value | — | — | — | — | — | 0.00 | (44.75) | (138.81) | (19.16) | (3.71) | |||||
| Shares, m | — | — | — | — | — | 38 | 0 | 1 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (27.03) | (4.28) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | (7) | (9) | (6) | ||||
| Capex | — | — | — | — | — | — | — | 0 | — | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (1) | (7) | (9) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | (1) | (14) | (16) | (8) | ||||
| Total debt | — | — | — | — | — | 0 | — | — | — | — | |||||
| Net debt | — | — | — | — | — | 0 | 0 | (1) | (3) | 0 | |||||
| Shareholders’ equity | — | — | — | — | — | 0 | (11) | (88) | (15) | (8) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 0.57 | (7.46) | (434.36) | (101.05) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | (15.90) | 23.50 | 33.68 | 24.90 | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Sep 2024
Charts ten years each
Abpro Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NEXI NexImmune, Inc. | $1.6M | — (loss-making) | — | — | n/m | +66.38% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.5M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ABPO Abpro Holdings Inc. | $1.4M | 0.2× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | |
| MLEC Moolec Science SA | $1.4M | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.3× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRC SciSparc Ltd. | $1.2M | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +85.35% (above 0%: growing) | (157.79%) | 0.00% | Compare |
| Median of peers | $1.4M | — | — | +251.41% | — | +30.51% | 0.00% | 0.00% |
Abpro Holdings Inc. (ABPO) key facts
- Strength: Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023.
- Abpro Holdings Inc. (ABPO) is a Biotechnology company in the Healthcare sector.
- As of October 16, 2026, ABPO traded at $0.36, a market capitalization of $1.4 million.
- Return on equity was 24.9% and debt-to-equity 0.00.
- Its Altman Z-score is −44.65 (distress zone) for fiscal 2024.